Why Is ImmunityBio Stock Gaining Wednesday?
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
Share
Why It Matters
ImmunityBio got permission from the FDA to sell its medicine to more patients. When a company's medicine gets approved, it usually means more people can buy it and use it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.